BioSpace News Archive

Exagen Inc., a leading provider of autoimmune testing solutions, announced that Paul Kim has been appointed as a member of the Exagen Board of Directors, effective July 24, 2023.

REGENXBIO Inc. (Nasdaq: RGNX) today announced three presentations at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting, taking place in Seattle, Washington from July 28 through August 1, 2023.

Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH), announced today that it will hold a conference call with PAH experts on Tuesday, July 25th at 10 a.m. EDT.

SomaLogic, Inc., a leader in proteomics technology, today announced that it will report financial results for the second quarter 2023 after market close on August 14th, 2023.

Cardiff Oncology, Inc. announced that on July 24, 2023, non-qualified stock option awards to purchase an aggregate of 50,016 shares of its common stock were granted to one new employee.

A presidential scholar from Pennsylvania is in Montreal this summer, applying her expertise to help a state-of-the-art lab at École Polytechnique de Montréal advance a breakthrough medical device that enables people with spinal cord injuries to move their limbs.

EpiBone has received Investigational New Drug (IND) clearance from the FDA to begin testing its lab-grown knee cartilage in humans.

Medicure Inc. (“Medicure” or the “Company”) (TSXV:MPH)(OTC PINK:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare products for patients and prescribers in the United States market, will present the 2023 Q2 Financial Results on a Conference Call on July 31, 2023 at 8:30 am Eastern Time.

VBI Vaccines Inc. today announced that the underwriters of its recent underwritten public offering of common shares.

DiaCarta, Ltd. today announced that the company has formed strategic partnership with New Jersey-based Hopkins MedTech Compliance (HMC) and Hopkins MedTech Lab Services (HML) to support the unmet needs for regulatory compliance and laboratory developed test (LDT) validation of in vitro diagnostics (IVD) in the United States.